Frank H. Valone

8.2k total citations · 2 hit papers
129 papers, 6.2k citations indexed

About

Frank H. Valone is a scholar working on Molecular Biology, Hematology and Immunology. According to data from OpenAlex, Frank H. Valone has authored 129 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 32 papers in Hematology and 30 papers in Immunology. Recurrent topics in Frank H. Valone's work include Hemoglobinopathies and Related Disorders (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers) and Platelet Disorders and Treatments (16 papers). Frank H. Valone is often cited by papers focused on Hemoglobinopathies and Related Disorders (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers) and Platelet Disorders and Treatments (16 papers). Frank H. Valone collaborates with scholars based in United States, Thailand and France. Frank H. Valone's co-authors include Edward J. Goetzl, Eric J. Small, Lori Jones, Charles H. Redfern, Robert M. Hershberg, Paul F. Schellhammer, Celestia S. Higano, John Nemunaitis, Madhusudan V. Peshwa and Reiner Laus and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Frank H. Valone

124 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

2006 840 citations Eric J. Small, Paul F. Schellhammer et al. Journal of Clinical Oncology profile →
Trends in Hip Arthroscopy Utilization in the United States

2013 359 citations Kevin J. Bozic, Vanessa Chan et al. The Journal of Arthroplasty profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank H. Valone United States	37	2.0k	2.0k	1.8k	1.3k	1.0k	129	6.2k
Kentaro Tanaka Japan	42	1.6k 0.8×	1.5k 0.8×	1.4k 0.8×	1.6k 1.3×	872 0.9×	307	6.7k
Anna Lokshin United States	48	2.4k 1.2×	1.7k 0.8×	2.3k 1.3×	970 0.7×	618 0.6×	137	6.7k
James W. Mier United States	40	2.8k 1.4×	2.7k 1.3×	3.3k 1.8×	1.8k 1.4×	583 0.6×	122	8.3k
Franco Silvestris Italy	41	2.5k 1.3×	1.8k 0.9×	2.6k 1.4×	630 0.5×	640 0.6×	216	7.5k
Matthew L. Sherman United States	41	2.1k 1.1×	2.2k 1.1×	3.2k 1.8×	945 0.7×	478 0.5×	134	7.8k
Elena Ranieri Italy	41	1.6k 0.8×	1.6k 0.8×	1.9k 1.1×	918 0.7×	592 0.6×	148	5.7k
Pieter Demetter Belgium	43	2.5k 1.2×	1.1k 0.5×	1.8k 1.0×	691 0.5×	1.2k 1.2×	199	6.4k
Naoyuki Kamatani Japan	51	1.0k 0.5×	1.3k 0.7×	2.8k 1.6×	799 0.6×	905 0.9×	179	8.9k
Poupak Fallahi Italy	59	2.1k 1.1×	2.1k 1.0×	1.9k 1.0×	865 0.7×	967 1.0×	298	10.8k
Hermann‐Josef Gröne Germany	44	790 0.4×	1.5k 0.8×	2.6k 1.5×	781 0.6×	700 0.7×	125	6.6k

Countries citing papers authored by Frank H. Valone

Since Specialization

Citations

This map shows the geographic impact of Frank H. Valone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank H. Valone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank H. Valone more than expected).

Fields of papers citing papers by Frank H. Valone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank H. Valone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank H. Valone. The network helps show where Frank H. Valone may publish in the future.

Co-authorship network of co-authors of Frank H. Valone

This figure shows the co-authorship network connecting the top 25 collaborators of Frank H. Valone. A scholar is included among the top collaborators of Frank H. Valone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank H. Valone. Frank H. Valone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Modi, Nishit B., et al.. (2024). Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers. Drugs in R&D. 24(4). 539–552. 2 indexed citations

Kremyanskaya, Marina, Andrew Kuykendall, Naveen Pemmaraju, et al.. (2024). Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. New England Journal of Medicine. 390(8). 723–735. 21 indexed citations

Wilson, Leslie, Patricia Zheng, Alina Denham, et al.. (2023). CAPER: patient preferences to inform nonsurgical treatment of chronic low back pain: a discrete-choice experiment. Pain Medicine. 24(8). 963–973. 1 indexed citations

Pemmaraju, Naveen, Marina Kremyanskaya, Andrew Kuykendall, et al.. (2023). MPN-541 Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera With the Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results of the Phase 2 Revive Study. Clinical Lymphoma Myeloma & Leukemia. 23. S400–S401.

Verstovšek, Srđan, Naveen Pemmaraju, Nancy L. Reaven, et al.. (2023). Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Annals of Hematology. 102(3). 571–581. 14 indexed citations

Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2016). FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. 2(1). 1–8. 8 indexed citations

Valone, Frank H., Russ Lyon, Jeremy A. Lieberman, & Shane Burch. (2014). Efficacy of Transcranial Motor Evoked Potentials, Mechanically Elicited Electromyography, and Evoked Electromyography to Assess Nerve Root Function During Sustained Compression in a Porcine Model. Spine. 39(17). E989–E993. 15 indexed citations

Valone, Frank H., Joseph N. Liu, Gillian L. Genrich, & Lisa Lattanza. (2013). Alveolar Rhabdomyosarcoma Causing Acute Compartment Syndrome of the Forearm: A Case Report and Review of the Literature. Journal of Hand and Microsurgery. 6(2). 92–95.

Bozic, Kevin J., Vanessa Chan, Frank H. Valone, Brian T. Feeley, & Thomas P. Vail. (2013). Trends in Hip Arthroscopy Utilization in the United States. The Journal of Arthroplasty. 28(8). 140–143. 359 indexed citations breakdown →

10.

Small, Eric J., Paul F. Schellhammer, Celestia S. Higano, et al.. (2006). Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer. Journal of Clinical Oncology. 24(19). 3089–3094. 840 indexed citations breakdown →

11.

Chong, Geoff, Anish Bhatnagar, David Cunningham, et al.. (2005). Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Annals of Oncology. 17(3). 437–442. 26 indexed citations

12.

Burch, Patrick, Gary A. Croghan, Dennis A. Gastineau, et al.. (2004). Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial. The Prostate. 60(3). 197–204. 156 indexed citations

13.

Przepiorka, Donna, Peter Van Vlasselaer, April Durett, et al.. (1996). Rapid Debulking and CD34 Enrichment of Filgrastim-Mobilized Peripheral Blood Stem Cells by Semiautomated Density Gradient Centrifugation in a Closed System. Journal of Hematotherapy. 5(5). 497–502. 10 indexed citations

14.

Valone, Frank H., Peter A. Kaufman, Paul M. Guyre, et al.. (1995). Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.. Journal of Clinical Oncology. 13(9). 2281–2292. 150 indexed citations

15.

Piedbois, Pascal, Marc Buyse, G.H. Blijham, et al.. (1994). Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Journal of Clinical Oncology. 12(5). 960–969. 162 indexed citations

16.

Shames, Richard, et al.. (1994). Tumor necrosis factor release by murine macrophages stimulated by the cytotoxic ether lipid 1-O-hexadecyl-2-O-methyl-SN-glycero-3-phosphorylcholine (ET-18-O-OCH3). International Journal of Immunopharmacology. 16(4). 335–343. 5 indexed citations

17.

Meyerhoff, Dieter J., Gregory S. Karczmar, Frank H. Valone, et al.. (1992). Hepatic Cancers and Their Response to Chemoembolization Therapy. Investigative Radiology. 27(6). 456–464. 19 indexed citations

18.

Valone, Frank H.. (1991). Synthesis of platelet-activating factor by human monocytes stimulated by platelet-activating factor. Journal of Allergy and Clinical Immunology. 87(3). 715–720. 7 indexed citations

19.

Shalit, Meir, Frank H. Valone, Paul C. Atkins, et al.. (1989). Late appearance of phospholipid platelet-activating factor and leukotriene B4 in human skin after repeated antigen challenge. Journal of Allergy and Clinical Immunology. 83(3). 691–696. 44 indexed citations

20.

Valone, Frank H., et al.. (1988). A Northern California Oncology Group Randomized Trial of Single Agent 5-FU vs. High-Dose Folinic Acid + 5-FU vs. Methotrexate + 5-FU + Folinic Acid in Patients with Disseminated Measurable Large Bowel Cancer. Advances in experimental medicine and biology. 244. 193–199. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact